|
|
|
Issue Open Date
|
07-Nov-25
|
|
|
|
Issue Closing Date
|
11-Nov-25
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
120
-
128
|
|
|
|
Minimium Application No.
|
2000
|
|
|
|
Issue Size (Shares)
|
2150000
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
|
Objective
|
|
i.Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities;ii.Capital Expenditure towards Construction of a Storage Facility;iii.Pre-payment/Repayment of outstanding Secured Loans;iv.Product Registrations in other countries;v.Funding our Working Capital Requirements; andvi.General Corporate Purpose.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
|
|
|
|
Qualified Institutional Buyers
|
|
|
|
|
Retail Individual Investors
|
|
|
|
|
|
|
|
Business Description:
Our business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic onloan license or contract Manufacturing and own brand marketing basis. Our business is majorly on principle to principlebasis with different marketers. As on the date of this Draft Red Herring Prospectus, we cater to more than 100 corporateclients on loan license and/or contract manufacturing basis along with 2 clients for own brand marketing globally ofRepublic of Yemen and Kenya. Our company has commenced manufacturing facility in year 2017, hence, our companyhas experience of more than 5 years in the current line of business of the company. as on the date of this Draft Red HerringProspectus our manufacturing facility at Curis Lifesciences Limited is installed with capacity to manufacture 138 Croretables / year, 15.75 Crore Capsules / year, 1080 Kilolitre Oral Liquid/ year, 270 Tons external preparation / year and 45Tons sterile ophthalmic ointment / year. Our promoters have a vast experience in the pharmaceutical manufacturingIndustry. Driven by the passion for building an integrated pharmaceutical company, backed by their experience, ourPromoters have been the pillars of our Company's growth and have built a strong value system for our Company. Withtheir enriching experience and progressive thinking, we aim to continue to grow in the pharmaceutical industry
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
5500000
|
|
|
|
Offered to Public
|
2150000
|
|
|
|
Promoter's Holding (Pre-Issue)
|
92.68
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
|
Address |
P F-23
G I D C
Sanand - I I
Industrial Estate
Sanand
Ahmedabad
,
Gujarat
,
382110
Phone :
7096558558
Email :
info@curisls.com
Website :
www.curisls.com
|
|
|
|
Registrar |
MUFG Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
|
|
|
|
Listed at |
|
NSE
|
|
|
|
Lead Manager |
|
Finaax Capital Advisors Pvt Ltd
|
|
|
|
Promoters |
Dharmesh Dashrathbhai Patel
Jaimik Mansukhbhai Patel
Piyush Gordhanbhai Antala
Siddhant Jayantibhai Pawasia
|
|
